Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 992,927 shares, a decrease of 52.8% from the September 15th total of 2,105,431 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 496,261 shares, the days-to-cover ratio is currently 2.0 days.
Rocket One Inc. Common Stock Stock Performance
RKTO traded down $0.03 during midday trading on Wednesday, reaching $0.54. The company had a trading volume of 146,564 shares, compared to its average volume of 4,227,593. The stock has a market cap of $12.11 million, a PE ratio of -0.66 and a beta of 0.90. Rocket One Inc. Common Stock has a 12-month low of $0.49 and a 12-month high of $2.45. The business has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.84.
Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.19) earnings per share for the quarter.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Rocket One Inc. Common Stock
Hedge Funds Weigh In On Rocket One Inc. Common Stock
An institutional investor recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC raised its position in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO – Free Report) by 100.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,000 shares of the company’s stock after purchasing an additional 19,500 shares during the period. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.08% of the company’s stock.
About Rocket One Inc. Common Stock
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
Further Reading
- Five stocks we like better than Rocket One Inc. Common Stock
- Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen
- Birkenstock’s Strong Growth Creates a Buying Opportunity
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
